CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced hERG Liability

1 code implementation • 12 Mar 2024 • Gregory W. Kyro, Matthew T. Martin, Eric D. Watt, Victor S. Batista

The link between in vitro hERG ion channel inhibition and subsequent in vivo QT interval prolongation, a critical risk factor for the development of arrythmias such as Torsade de Pointes, is so well established that in vitro hERG activity alone is often sufficient to end the development of an otherwise promising drug candidate.

Drug Discovery